2008-09-10 23:56:04 -
www.researchandmarkets.com - Research and Markets (www.researchandmarkets.com/research/b763bd/outcomesbased_pha) has announced the addition of the "Outcomes-Based Pharmaceutical Pricing" report to their offering.
Source: Cutting Edge Information
Optimize pricing planning to satisfy customer group needs in this report from Cutting Edge Information:
The pricing landscape has changed dramatically over the past decade. In the 1990s and even a few years ago,
pricing was almost an afterthought -- pricing plans were formed and carried out during ramp-up to product launch; there was less regulatory scrutiny; the concept of health outcomes analysis was still taking shape, and any pharmacoeconomic data that companies were able to provide was better than none.
Today, however, strategic pricing is more important than ever before. Pharmaceutical and biotechnology companies' pricing teams contend with unrelenting pressures. They must manage increased scrutiny from different sides -- government agencies, the media and the public -- over pharmaceutical pricing, while meeting multiple stakeholders' needs: third-party payers, physicians and patients. Adding to the complexity are ever-rising clinical development costs and shrinking pipelines in a constantly changing, global marketplace.
As a result of these challenges, pharmaceutical pricing has become payer-driven and value-based. But life sciences companies are also recognizing the vital importance of strategic pricing. Rather than coming at the tail end of a drug's development, pricing planning is being integrated into drug development. The pricing department, in fact, is now a key driver in lifecycle management.
Outcomes-Based Pharmaceutical Pricing: Meeting Stakeholder Needs examines these industry trends. It provides action items to resolve pricing departments' most pressing problems. Above all, it shows how forward-thinking companies maximize profits by addressing customers' preferences and ensuring that they set the right prices for their products. -0- Use the report to: - Maximize pricing departments' strategic capabilities - Improve pricing decision making - Streamline the pricing process - Coordinate pricing and launch sequence strategies - Improve cross-functional communication and involvement in pricing plans - Benchmark pricing department resources Key Topics Covered: - Profiled Companies - Strategic Pricing: Five Principles for Success - Pricing Challenges - Processes and Methodology - Structure and Budgets - List of Figures Companies Mentioned: - ApoPharma - Astellas Pharmaceuticals - Aveo Pharmaceuticals - Bausch & Lomb - Baxter - Bayer HealthCare - Biogen Idec - Carter/Sigma-Tau - Celgene - CellPoint Diagnostics - CV Therapeutics - Daiichi Sankyo - Exelixis - Genentech - Industria Biotecnologica Von Meiding - Johnson & Johnson - Leo Pharma - MediCepts - MedImmune - Medtronic - Merck & Co. - Myriad Pharmaceuticals - NovaDel Pharma - Novartis Pharmaceuticals - Pamlab - Pfizer - PharmaDerm - ViroPharma - Wyeth Pharmaceuticals - Xanodyne Pharmaceuticals
For more information visit
www.researchandmarkets.com/research/b763bd/outcomesbased_pha
Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
